Dr. Aleksandar Sekulic on Vismodegib for Basal-Cell Nevus Syndrome

Aleksandar Sekulic, MD, PhD, Assistant Professor of Dermatology, Mayo Clinic, Scottsdale, AZ, discusses the use of the oral hedgehog pathway inhibitor vismodegib (Erivedge) for the treatment and prevention of basal-cell carcinoma (BCC) in patients with basal-cell nevus syndrome, a rare disorder also known as Gorlin syndrome.

For more resources on skin cancer and melanoma, visit http://www.onclive.com/specialty/melanoma